In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Addrenex makes appointments

This article was originally published in Scrip

Executive Summary

Addrenex Pharmaceuticals, a two-year-old US firm, has appointed Steven Butts vice-president of commercial affairs, Dr Gary Bream senior director of scientific affairs, and Yuki Prescott clinical trials manager. Mr Butts has worked at Biobehavioral Diagnostics and Lilly, while Dr Bream and Ms Prescott most recently served at Constella. Addrenex has filed a sustained-release clonidine product, CloniBID, for US approval in hypertension, and has an extended-release clonidine, Clonicel, in Phase III trials for attention deficit hyperactivity disorder; both products will be marketed by licensee Sciele Pharma.

Topics

Related Companies

UsernamePublicRestriction

Register

SC000415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel